Shenzhen TargetRx, Inc. Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2014

Location

Shenzhen Guangdong China

Primary Industry

Pharmaceuticals

About

Established in 2014 based in Shenzhen, China, Shenzhen TargetRx, Inc. operates as an anti-cancer drug developer focusing on research, development, sales, and service of targeted drugs for cancer therapy. The company has more than 200 inventions patented in China, the USA, Europe, and Japan. The company's Founder, Chairman, and CEO, Yihan Wang graduated from the Department of Chemistry of New York University. He is one of the co-founders of the Chinese American Biomedical Association (CABA). The company has partnerships with CCB International, Shenzhen Capital Group, Shenzhen Acacia Investment, and Shenzhen Leaguer Tsing-Yuan Venture Capital Management. The company's products can be categorized into the next-generation Bcr-Abl allosteric inhibitor TGRX-678, and the third-generation ALK inhibitor TGRX-326, which have both conducted the dosing of the first subject in Phase I studies. The TGRX-326 is used to treat non-small cell lung cancer (NSCLC). The TGRX-678 is used to treat chronic myelogenous leukemia (CML).

Current Investors

SEEDS Capital, Shenzhen Capital Real Estate Fund, Beijing Shengrui Zhongle Consulting service

Request a demo to show more

Primary Industry

Pharmaceuticals

Sub Industries

Biopharmaceuticals, Oncology/Cancer Treatment, Pharmaceuticals

Website

www.tjrbiosciences.com

Verticals

HealthTech, Manufacturing

Company Stage

Series B

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.